Healthcare
Zymeworks Inc.(ZYME)
Live Price
Offline$23.14
+0.00% today
1Y Change
+85.57%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $1.99B
- Revenue Growth
- +38.9%
- EPS Growth
- +33.3%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zymeworks Inc. (ZYME) is a Healthcare stock with a market cap of $1.99B and listed on NASDAQ. The stock last traded around $23.14 and up 85.6% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +38.9%, EPS growth of +33.3%, a dividend yield of 0.0%. What stands out right now is revenue +38.9%, EPS +33.3%, free cash flow +69.5% with operating margin -87.3% and ROIC -30.1%. Valuation already assumes a fairly strong business story at price/sales 18.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZYME price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+38.9% vs +7.6% peer median
Operating Margin
Below sector median
-87.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +38.9% and EPS at +33.3%, with operating margin around -87.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.1% | +4.8% | -4.5% |
2026 Mar 2, 2026 | -57.1% | +4.9% | +4.0% | +3.9% |
2025 Nov 6, 2025 | +13.3% | -8.0% | +3.4% | +49.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZYME
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZYME Max Drawdown
-21.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZYME and SPY.
Company Overview
Zymeworks Inc.
NASDAQ Global Select
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
- Leadership
- Kenneth H. Galbraith
- IPO Date
- Apr 28, 2017
- Employees
- 299
- Street Address
- 114 East 4th Avenue
- Mailing
- Middletown, BC, V5T 1G4
- Region
- Middletown, BC, CA
- Reporting Currency
- USD
- Investor Line
- 16046781388
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 18.8
- Price/Book
- 7.5
Growth
- Revenue
- +38.9%
- EPS
- +33.3%
- Free Cash Flow
- +69.5%
Profitability
- Gross Margin
- 98.4%
- Operating Margin
- -87.3%
- Net Margin
- -76.6%
- ROE
- -26.0%
- ROIC
- -30.1%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 5.52
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.